Thalia Therapeutics plc (AIM: THAT), a clinical-stage RNA therapeutic company focused on oncology and cardiovascular disease, has announced promising interim Phase I data for its lead oncology asset, miRisten™ (THAT-001), in patients with acute myeloid leukaemia (AML). The 16 November 2026 announcement represents the first clinical dataset for Thalia since adopting its current strategy as an RNA-based therapeutics business. Nine heavily pretreated patients have been dosed across two completed dose levels, with early evidence of target engagement, biological activity, and an encouraging safety profile observed in the trial conducted at City of Hope in California.

Key Points

  • Thalia Therapeutics plc (AIM: THAT) is a clinical-stage biotechnology company developing RNA-based therapeutics in oncology and cardiovascular disease
  • Interim Phase I data for miRisten™ in AML show the therapy is generally well tolerated with early signs of biological and clinical activity across nine treated patients
  • Eight of nine patients experienced no dose-limiting toxicity; one patient achieved a transient complete response with neutrophil recovery persisting for over a year
  • Investors should watch for the topline Phase I readout, targeted for the first half of 2027

miRisten™ Mechanism: Targeting Leukaemia Stem Cells via Anti-miR-126 Inhibition

MiRisten™ is a first-in-class anti-miR-126 therapeutic engineered to address a fundamental limitation of standard AML treatment: the survival of leukaemia stem cells (LSCs) in the protective bone marrow microenvironment. Conventional chemotherapy targets rapidly dividing cancer cells but routinely fails to eliminate dormant LSCs, which subsequently drive disease relapse. By inhibiting miR-126, miRisten™ aims to disrupt this protective niche and render LSCs susceptible to chemotherapeutic agents, including venetoclax. Research published in the peer-reviewed journal Blood demonstrated enhanced antileukemic activity of venetoclax when combined with miRisten™ in preclinical AML models.

Phase I Interim Results: Target Engagement and Clinical Activity Observed in Nine AML Patients

Nine patients with relapsed or refractory AML, with a median age of 55 and a median of four prior lines of treatment, have been dosed with miRisten™. The announcement states that upon infusion, miRisten™ is immediately detectable in pharmacokinetic assays, with simultaneous reductions in miR-126 target levels and a preliminary increase in SPRED1, a pharmacodynamic endpoint, all consistent with successful target engagement. Eight patients experienced no dose-limiting toxicity. Post-treatment reductions in leukaemic blast cells and improvements in neutrophil levels were observed, with one patient achieving a transient complete response and neutrophil recovery persisting for over a year.

City of Hope Partnership and Thalia's Exclusive Commercialisation Rights via Sanmirna

The single-centre, open-label trial is being conducted at City of Hope in Los Angeles, California, ranked among America's leading cancer centres by U.S. News & World Report. Thalia's wholly-owned US subsidiary, Sanmirna Therapeutics Inc., holds an exclusive licence from City of Hope to develop and commercialise miRisten™. A Clinical Trial Agreement grants Thalia access to clinical data, including the interim results disclosed in this announcement. The company notes that City of Hope holds an equity interest in Thalia, a structural relationship investors may wish to consider when evaluating governance and commercialisation arrangements.

Topline Phase I Data Targeted for H1 2027 as Third Dose Level Enrolment Continues

The third and final dose level of the monotherapy trial is currently enrolling its last patients, with topline data targeted for the first half of 2027. The announcement describes this interim readout as the first clinical data for Thalia since embarking on its strategy as a clinical-stage RNA therapeutic company, and an important safety and efficacy milestone for miRisten™. The broader AML context is clinically significant: approximately 23,000 people are diagnosed with AML annually in the United States, with five-year survival across all patients at 33.4%, and median survival in relapsed or refractory patients consistently below 12 months.